<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844555</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505-118-13</org_study_id>
    <secondary_id>2018-002481-39</secondary_id>
    <nct_id>NCT03844555</nct_id>
  </id_info>
  <brief_title>Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients</brief_title>
  <official_title>Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of Elafibranor 120 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted in order to assess the need for dose adjustment for elafibranor&#xD;
      in participants with renal impairment. Pharmacokinetic parameters of elafibranor and its&#xD;
      active metabolite (GFT1007) will be compared in severe renal impaired participants&#xD;
      (eGFR&lt;15mL/mn/1.73m^2) versus healthy participants after a single oral administration of&#xD;
      elafibranor 120 mg&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Actual">March 21, 2020</completion_date>
  <primary_completion_date type="Actual">March 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and active metabolite</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>In participants with end stage renal disease compared to healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve from dosing time to infinity (AUC(0-∞)) of elafibranor and active metabolite</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>In participants with end stage renal disease compared to healthy volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: maximum plasma drug concentration (Cmax)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: elimination half-life (t1/2)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: apparent volume of distribution (Vd/F)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for elafibranor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: renal clearance (CLr)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: apparent non renal clearance (CLnr/F)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for elafibranor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: apparent total clearance (CL/F)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for elafibranor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total area under the plasma concentration-time curve (%AUCextra)</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: area under curve from dosing time to last measurement (AUC(0-t)) of glucuronide metabolites and corresponding aglycones</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for the glucuronide metabolites of elafibranor and corresponding aglycones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: area under curve from dosing time to infinity (AUC(0-∞)) of glucuronide metabolites and corresponding aglycones</measure>
    <time_frame>pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose</time_frame>
    <description>for the glucuronide metabolites of elafibranor and corresponding aglycones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: amount excreted (Ae)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: cumulative amount excreted (Ae0-t)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: percentage of dose excreted (Fe)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: cumulative percent of dose excreted (Fe0-t)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: renal clearance (CLR)</measure>
    <time_frame>pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose</time_frame>
    <description>for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Renal Impairment</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Kidney Diseases</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>End Stage Renal Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of elafibranor 120mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of elafibranor 120mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elafibranor</intervention_name>
    <description>120mg oral single dose</description>
    <arm_group_label>End Stage Renal Disease</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <other_name>GFT505</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all participants&#xD;
&#xD;
          1. Male or female subjects, aged 18 to 75 years inclusive;&#xD;
&#xD;
          2. Females participating in this study must be of non-childbearing potential or using&#xD;
             highly efficient contraception for the full duration of the study&#xD;
&#xD;
          3. Negative serum pregnancy test at screening (if applicable);&#xD;
&#xD;
          4. Non-smoker subject or smoker of not more than 5 cigarettes a day;&#xD;
&#xD;
             For Renally Impaired Participants&#xD;
&#xD;
          5. ESRD patient not yet on dialysis with an estimated glomerular filtration rate (eGFR)&#xD;
             &lt;15mL/min/1.73m^2;&#xD;
&#xD;
          6. Documented renal impairment indicated by reduced eGFR within 12 months of screening or&#xD;
             longer;&#xD;
&#xD;
          7. Stable renal function as evidenced by ≤ 30 percent difference in two evaluation of&#xD;
             eGFR on two separate occasions separated by at least 28 days with one measurement&#xD;
             being the value at screening;&#xD;
&#xD;
          8. Body Mass Index (BMI) between 20 and 36 kg/m^2 inclusive.&#xD;
&#xD;
             For Healthy Volunteers with normal renal function:&#xD;
&#xD;
          9. eGFR ≥ 90mL/min/1.73m^2;&#xD;
&#xD;
         10. No proteinuria (&lt; 0.15 g/L determined by urinalysis);&#xD;
&#xD;
         11. Body Mass Index between 20 and 30 kg/m^2 inclusive and body weight not lower than&#xD;
             55kg;&#xD;
&#xD;
         12. Matched to at least 1 renal impaired patient by ethnic group, sex, age (+/- 10 years)&#xD;
             and BMI (+/- 20 percent).&#xD;
&#xD;
        Other protocol-defined inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Participants&#xD;
&#xD;
          1. Positive Hepatitis B surface antigen or anti Hepatitis C Virus antibody, or positive&#xD;
             results for Human Immunodeficiency Virus 1 or 2 tests;&#xD;
&#xD;
          2. History or presence of drug or alcohol abuse (alcohol consumption &gt; 40 grams/day);&#xD;
&#xD;
          3. Blood donation (including in the frame of a clinical trial) within 2 months before&#xD;
             administration or blood donation planned during the study or within 2 months following&#xD;
             participation to the study;&#xD;
&#xD;
          4. Participants who are pregnant or breastfeeding. Participants should not be enrolled if&#xD;
             they plan to become pregnant during the time of study participation;&#xD;
&#xD;
          5. Positive results of screening for drugs of abuse;&#xD;
&#xD;
          6. Evidence or history of clinically significant uncontrolled hematological, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic,&#xD;
             metabolic, systemic, infectious, or allergic disease (including drug hypersensitivity&#xD;
             or allergies, but excluding untreated, asymptomatic, seasonal allergies at time of&#xD;
             dosing);&#xD;
&#xD;
          7. General anesthesia within 3 months before administration;&#xD;
&#xD;
          8. Major surgery within 28 days prior to randomization or major surgery planned during&#xD;
             the next 6 months.&#xD;
&#xD;
             For Renally Impaired Participants:&#xD;
&#xD;
          9. History of renal transplant;&#xD;
&#xD;
         10. Evidence of an unstable clinically important medical condition other than impaired&#xD;
             renal function;&#xD;
&#xD;
         11. Acute exacerbation or unstable renal function, as indicated by worsening of clinical&#xD;
             and/or laboratory signs of renal impairment, within the 4 weeks before study drug&#xD;
             administration;&#xD;
&#xD;
         12. Participants undergoing any method of dialysis or hemofiltration;&#xD;
&#xD;
         13. Disorders or surgery of the gastrointestinal tract which may interfere with drug&#xD;
             absorption or may otherwise influence the pharmacokinetics of the investigational&#xD;
             medicinal product (e.g., inflammatory bowel disease, resections of the small or large&#xD;
             intestine, etc.);&#xD;
&#xD;
         14. History of febrile illness within 5 days prior to dosing;&#xD;
&#xD;
         15. Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or&#xD;
             C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease,&#xD;
             elevated aspartate aminotransferase or alanine aminotransferase that is considered&#xD;
             clinically significant by the Investigator, etc.). Presence or history of protein drug&#xD;
             hypersensitivity, or allergic disease diagnosed and treated by a physician&#xD;
&#xD;
         16. Any drug intake during the 2 weeks or 5 half-life of the drug preceding the first&#xD;
             administration except those defined in the protocol&#xD;
&#xD;
             For Healthy Volunteers with normal renal function:&#xD;
&#xD;
         17. Any history or presence of renal disease&#xD;
&#xD;
         18. Frequent headaches (&gt; twice a month) and / or migraines, recurrent nausea and / or&#xD;
             vomiting;&#xD;
&#xD;
         19. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic&#xD;
             postural hypotension defined by a decrease in Systolic Blood Pressure (≥20 mmHg) or&#xD;
             Diastolic Blood Pressure (≥10 mmHg) within three minutes when changing from the supine&#xD;
             to the standing position;&#xD;
&#xD;
         20. Inability to abstain from intensive muscular effort;&#xD;
&#xD;
         21. Any drug intake (except paracetamol 3g/d or contraception) during the 2 weeks or 5&#xD;
             half-life of the drug preceding the first administration;&#xD;
&#xD;
         22. Subject who would receive more than 4500 euros as indemnities for his participation in&#xD;
             biomedical research within the 12 last months, including the indemnities for the&#xD;
             present study.&#xD;
&#xD;
        Other protocol-defined exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Birman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genfit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Unit, Nephrology Hospital Dr. Carol Davilla</name>
      <address>
        <city>Bucharest</city>
        <zip>010701</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

